CN118475347A - 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 - Google Patents

用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 Download PDF

Info

Publication number
CN118475347A
CN118475347A CN202280085098.8A CN202280085098A CN118475347A CN 118475347 A CN118475347 A CN 118475347A CN 202280085098 A CN202280085098 A CN 202280085098A CN 118475347 A CN118475347 A CN 118475347A
Authority
CN
China
Prior art keywords
methyl
carboxamide
thiazole
bipiperidin
difluoropyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280085098.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·德尔贝克
M·哈恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN118475347A publication Critical patent/CN118475347A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280085098.8A 2021-12-22 2022-12-20 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物 Pending CN118475347A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21216872 2021-12-22
EP21216872.8 2021-12-22
PCT/EP2022/086965 WO2023118123A1 (en) 2021-12-22 2022-12-20 Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea

Publications (1)

Publication Number Publication Date
CN118475347A true CN118475347A (zh) 2024-08-09

Family

ID=80225456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280085098.8A Pending CN118475347A (zh) 2021-12-22 2022-12-20 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C（α-2C）拮抗剂与降肾上腺素重摄取抑制剂的结合物

Country Status (11)

Country Link
US (1) US20250049779A1 (https=)
EP (1) EP4452242A1 (https=)
JP (1) JP2025500344A (https=)
KR (1) KR20240124995A (https=)
CN (1) CN118475347A (https=)
AU (1) AU2022418121A1 (https=)
CA (1) CA3256789A1 (https=)
IL (1) IL313646A (https=)
MX (1) MX2024007768A (https=)
TW (1) TW202342033A (https=)
WO (1) WO2023118123A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
HRP20041026A2 (en) 2002-04-03 2005-06-30 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2017031319A1 (en) 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
GEAP202416602A (en) 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.
PE20221025A1 (es) 2019-11-06 2022-06-16 Bayer Ag Inhibidores de los receptores a2c adrenergicos

Also Published As

Publication number Publication date
WO2023118123A1 (en) 2023-06-29
US20250049779A1 (en) 2025-02-13
JP2025500344A (ja) 2025-01-09
TW202342033A (zh) 2023-11-01
EP4452242A1 (en) 2024-10-30
AU2022418121A1 (en) 2024-07-04
MX2024007768A (es) 2024-07-01
KR20240124995A (ko) 2024-08-19
IL313646A (en) 2024-08-01
CA3256789A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20220218700A1 (en) Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
JP7592007B2 (ja) 睡眠時無呼吸の治療のためのα２‐アドレナリン受容体サブタイプＣ （ＡＬＰＨＡ‐２Ｃ）拮抗薬
US20220218695A1 (en) Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
TW202216141A (zh) 用以治療睡眠呼吸終止之α2-腎上腺素受體C亞型(α-2C)拮抗劑與TASK1/3通道阻斷劑的組合
US20250049779A1 (en) Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
US20250057828A1 (en) Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
HK40116247A (zh) 用於治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C(α-2C)拮抗剂与降肾上腺素重摄取抑制剂的结合物
HK40114784A (zh) 用於治疗睡眠呼吸暂停的α 2-肾上腺素受体亚型C(α -2C)拮抗剂与毒蕈碱受体拮抗剂的结合物
HK40115354A (zh) 用於治疗睡眠呼吸暂停的2 ,3-二氢苯并[b][1，4]二恶英-2-基甲基)哌嗪-1-基衍生物
CN113166166B (zh) 用于治疗睡眠呼吸中止的α2-肾上腺素受体亚型C(α-2C)拮抗剂
US20250049788A1 (en) 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea
HK40049552A (en) α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
HK40115453A (zh) 用於治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂
EA045860B1 (ru) АНТАГОНИСТЫ α2-АДРЕНОРЕЦЕПТОРОВ ПОДТИПА С (АЛЬФА-2С АДРЕНОРЕЦЕПТОРОВ) ДЛЯ ЛЕЧЕНИЯ АПНОЭ ВО СНЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116247

Country of ref document: HK